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Seropositive HIV is related to seropositive HDV 527Human
immunodeficiency
virus;
Injecting drug users;
Taiwanaim of this study is to explore the conditions of HDV infections between injecting drug users
(IDUs) with and without HIV infection in Southern Taiwan. In this study, 87 IDUs were enrolled,
including 27 anti-HDV seronegative IDUs and 60 anti-HDV seropositive IDUs, and the results of
their liver function tests, CD4 cell counts, and anti-HIV and HIV RNA levels were analyzed. The
prevalence of anti-HDV seropositivity among hepatitis B surface antigen (HBsAg) seropositive
IDUs in this study was 68.9% (60/87). The prevalence rate of anti-HDV seropositive IDUs among
anti-HIV seronegative and anti-HIV seropositive cases was 40.0% (12/30) and 84.2% (48/57),
respectively. Anti-HIV seropositivity was related to anti-HDV seropositivity (odds
ratio Z 9.34, 95% confidence interval Z 2.67e31.59, p < 0.001). Among IDUs with HIV infec-
tion, there was no significant difference in CD4 cell counts and HIV RNA viral load between
HBsAg-positive patients with anti-HDV seronegativity and those with anti-HDV seropositivity.
In conclusion, the prevalence of HDV infection among IDUs is higher among IDUs with HIV infec-
tion. Because anti-HIV seropositivity is significantly related to anti-HDV seropositivity, HDV
infection among IDUs is still important. We suggest that for IDUs, HBsAg and anti-HDV should
be monitored closely.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Hepatitis D virus (HDV) is a defective virus, which requires
life-cycle function provided by the hepatitis B virus (HBV)
[1]. HDV is reported globally, with more than 10 million
people currently infected with the virus [2]. Estimates
suggest that there are about 370 million individuals with
chronic HBV infection [3], about 40 million individuals with
human immunodeficiency virus (HIV) infections [4], and
3e6 million HIV-infected individuals coinfected with
chronic HBV [5]. In addition, it was estimated that about 5%
of HBV carriers are coinfected with HDV, and thus, there
are about 15 million individuals infected with HDV world-
wide [6]. HDV coinfection with HBV may lead to exacer-
bation and rapid progression of chronic liver disease among
HBV monoinfected individuals [7], and HDV can increase
the risk of decompensated liver disease and death of HBV/
HIV coinfected individuals [8,9].
Because HBV and HIV share common routes of trans-
mission, especially blood-borne transmission, such as
injecting drug use [10], injecting drug use is a very impor-
tant cause of HBV infection worldwide [11]. As a result,
HDV transmission can also spread with HBV via a similar
route.
One study in the United States reported that HDV prev-
alence among injection drug users was 15% in 1988e1989
and 11% in 2005e2006 [12]. In Taiwan, injecting drug use
has been the main route of transmission of HIV since 2005
[13], with HDV also being prevalent among injecting drug
users (IDUs; 75.4% among IDUs with HIV infection and 66.1%
among IDUs without HIV infection in 2006) [14].
Because the prevalence of chronic HBV infection in
Taiwan is about 15e20% among the general population born
before the implementation of a nationwide HBV vaccina-
tion program in 1984 [15], HDV infection might be higher
among those born before 1984, compared with those born
after 1984. Therefore, the aim of this study was to explore
the conditions of HDV infections among IDUs with and
without HIV infection in Southern Taiwan.Methods
Study participants
We enrolled IDUs from three prisons and Kaohsiung Medical
University Chung-Ho Memorial Hospital (Kaohsiung City,
Taiwan) from March 2008 to June 2010. We excluded in-
dividuals with severe liver, renal, or other systemic disease,
such as decompensated hepatic failure, renal failure, any
malignant disease, or severe heart failure, etc. This study
was approved by the ethics committee of Kaohsiung Medi-
cal University Hospital. Signed informed consents were
obtained from all participants.
Laboratory data
We measured the levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), hepatitis B surface
antigen (HBsAg), anti-HIV antibody, HIV RNA viral load, CD4
cell count, and anti-HDV antibody. HBsAg was examined by
enzyme immunoassay (EIA; Abbott Laboratories, North
Chicago, IL, USA). Anti-HIV antibody assay (SERODIA-HIV;
Fujirebio, Tokyo, Japan) was performed according to the
manufacturer’s instructions. HIV viral loads were quantified
using reverse transcription-polymerase chain reaction
(Roche Amplicor, version 1.5; Roche Diagnostics, Branch-
burg, NJ, USA), and CD4 counts were determined using
FACFlow (BD FACSCalibur; Becton Dickinson, San Jose, CA,
USA). Anti-HDV antibody was examined using an AUSAB EIA
kit (Abbott Laboratories, Abbott Park, IL, USA).
Statistical analysis
Statistical tests used in this study were Student t test and
the c2 square test. In addition, multivariate analysis was
used for estimating the odds ratios (ORs) and 95% confi-
dence intervals (CIs). All of these tests were two sided, and
the significance levels were set at a Z 0.05. All statistical
Table 2 Multivariate analysis for evaluating factors of
528 M.-H. Hsieh et al.analysis were performed using the SPSS statistical package
(SPSS Inc., Chicago, IL, USA).anti-HDV seropositivity among HBsAg seropositive injecting
drug users.
Factors Comparison Odds
ratio
95% Confidence
interval
p
Anti-HIV 0 Z negative;
1 Z positive
9.34 2.76e31.59 <0.001
Sex 0 Z male;
1 Z female
1.36 0.36e5.24 0.65
Age Increasing
by 1 y
0.99 0.92e1.07 0.82
Factors used for analysis were anti-HIV, sex, and age.
CIZ confidence interval; HBsAgZ hepatitis B surface antigen;
HDVZ hepatitis D virus; HIVZ human immunodeficiency virus.Results
In this study, 87 HBsAg seropositive IDUs were enrolled,
including 60 anti-HDV seropositive IDUs and 27 anti-HDV
seronegative IDUs. The prevalence of anti-HDV seroposi-
tivity among HBsAg seropositive IDUs was 68.9% (60/87) in
this study.
Table 1 shows the basic characteristics of anti-HDV
seropositive and seronegative IDUs among the 87 HBsAg
seropositive IDUs studied. There was a male predominance
among anti-HDV seronegative and seropositive IDUs. Uni-
variate analysis showed a statistical significance (p < 0.001)
in the association between anti-HIV and anti-HDV, and the
prevalence rate of anti-HDV seropositive IDUs among anti-
HIV seronegative and seropositive cases was 40.0% (12/30)
and 84.2% (48/57), respectively. Lower HIV RNA viral load
and higher CD4 cell count were noted in anti-HDV sero-
positive IDUs. Although AST and ALT ratios were also higher
among anti-HDV seropositive IDUs, no significant associa-
tion was noted (Table 1).
The factors related to seropositive anti-HDV among
HBsAg seropositive IDUs were analyzed by multivariate
analysis. Anti-HIV seropositivity was the factor of anti-HDV
seropositivity among HBsAg seropositive IDUs in this study
(OR Z 9.34, 95% CI Z 2.76e31.95; Table 2).Table 1 Basic characteristics of anti-HDV seropositive and
seronegative injecting drug users among the 87 HBsAg
seropositive injecting drug users in this study.
Univariate analysis
Anti-HDV
seronegative
Anti-HDV
seropositive
p
Total, n (%) 27 (100.0) 60 (100.0)
Age (y) 33.04  7.97 35.66  6.26 0.69
Sex
Male, n (%) 18 (67.7) 50 (83.3) 0.82
Female, n (%) 9 (33.3) 10 (16.7)
Aspartate
aminotransferase
(ratio for UNL)
0.87  0.47 0.97  0.54 0.44
Alanine
aminotransferase
(ratio for UNL)
1.03  0.92 1.23  0.78 0.35
Anti-HIV
Seronegative, n (%) 18 (67.7) 12 (20.0) <0.001
Seropositive, n (%) 9 (33.3) 48 (80.0)
HIV RNA, log(IU/mL)a 3.38  0.42 3.15  0.77 0.40
CD4 cell counta 385.33 
120.56
459.44 
159.52
0.19
>500 cells/mL 1 (11.1) 21 (43.8) 0.65
<500 cells/mL 8 (88.9) 27 (56.3)
HBsAg Z hepatitis B surface antigen; HDV Z hepatitis D virus;
HIV Z human immunodeficiency virus; UNL Z upper normal
limit.
Bold value means p < 0.05.
a For 57 anti-HIV seropositive individuals.We also performed a multivariate analysis for identifying
factors responsible for abnormal levels of AST and ALT
(Table 3). Unfortunately, no factor was identified. Howev-
er, anti-HIV showed the highest OR value for abnormal AST
(OR Z 3.24) and ALT (OR Z 2.99) levels among all factors
evaluated.
Discussion
HDV is prevalent in the Amazon Basin, the Mediterranean
Basin, and Central Africa. It is spread by close contact and
is endemic to many Mediterranean countries. In the United
States, HDV is confined to individuals exposed to contami-
nated blood [2]. Globally, about 5% of the HBsAg carriersTable 3 Multivariate analysis for evaluating factors
responsible for abnormal AST and ALT levels among HBsAg
seropositive injecting drug users.
Factors Comparison Odds ratio 95% CI p
AST
Anti-HDV 0 Z negative;
1 Z positive
1.66 0.49e5.67 0.42
Anti-HIV 0 Z negative;
1 Z positive
3.24 0.78e13.45 0.11
Sex 0 Z male;
1 Z female
1.63 0.39e6.77 0.50
Age Increasing
by 1 y
0.99 0.92e1.06 0.74
ALT
Anti-HDV 0 Z negative;
1 Z positive
0.64 0.21e1.94 0.42
Anti-HIV 0 Z negative;
1 Z positive
2.99 0.84e10.68 0.09
Sex 0 Z male;
1 Z female
1.01 0.28e3.62 0.99
Age Increasing
by 1 y
0.94 0.88e1.01 0.11
Factors for analyzing are anti-HDV, anti-HIV, sex, and age.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; CI Z confidence interval; HBsAg Z hepatitis B
surface antigen; HDV Z hepatitis D virus; HIV Z human im-
munodeficiency virus.
Seropositive HIV is related to seropositive HDV 529are also infected by HDV [16]; this rate is slightly higher in
Europe (14.5%) [17]. However, after the implementation of
HBV vaccination programs since the 1990s, the prevalence
of HDV has consistently declined in the developed countries
[16]. In Taiwan, 6.7% of chronic hepatitis B patients were
positive for anti-HDV [18]. The prevalence of HDV infection
among IDUs is 0% in Brazil [19] and 1.6% (2/122) in Spain
[20]. However, from a previous study in Taiwan, 85% of
HBsAg-positive carriers with drug abuse were positive for
anti-delta [21]. In this study, the prevalence of anti-HDV
seropositivity among HBsAg seropositive IDUs was 68.9%.
Thus, in Taiwan, the prevalence of HDV infection is higher
among IDUs; in fact, this HDV prevalence is also higher than
that in Brazil and Spain. Thus, these data suggest that HDV
infection among IDUs is severe in Taiwan. Although the
underlying reason for this high prevalence rate is unclear,
this issue should be addressed immediately.
HIV/HBV patients are at a potential risk of HDV infec-
tion; therefore, examining the presence of HDV infection is
necessary in these patients. One study reported that of the
26 HDV seropositive general participants studied, 61.5%
(16/26) exhibited HIV seropositivity [22]. In another study
in Brazil, 1.2% (1/86) of HIV/HBV coinfected patients were
found to be anti-HDV seropositive [23]. In addition, the
prevalence of anti-HDV in chronic HBsAg-positive/HIV car-
riers in EuroSIDA was 14.5% (61/422), with hepatitis D being
predominant among intravenous drug users, which explains
why hepatitis delta predominated in southern and/or
eastern Europe [17]. A previous study in Taiwan showed
that HDV is also prevalent among IDUs (75.4% among IDUs
with HIV infection and 66.1% among IDUs without HIV
infection in 2006) [14], with an another study, also con-
ducted in Taiwan, showing that the prevalence rates of HDV
infection were 74.9% and 43.9% among HIV-infected IDUs
and HIV-uninfected IDUs, respectively [24]. In our study,
the prevalence of anti-HDV seropositivity among HBsAg
seropositive individuals was 84.2% (48/57) among IDUs with
HIV infection and 40.0% (12/30) among IDUs without HIV
infection. Although the difference between these two
studies could be attributed to differences in the back-
grounds of the participants, our study result indicates a
higher prevalence of anti-HDV seropositive IDUs among IDUs
with HIV infection than previous studies in Taiwan [14,24].
The authors opine that HDV infection among IDUs has
gradually become severe over the years in Taiwan.
Furthermore, in this study, anti-HIV seropositivity was
found to be related to anti-HDV seropositivity, so we sug-
gest that for IDUs, including HBsAg seropositive individuals
whose HBV DNA is undetectable, anti-HDV screening is
necessary.
In this study, the ratios of AST and ALT were higher
among IDUs with HDV infection, although no significant
difference was noted. In addition, none of the factors
studied was related to abnormal ratios of AST and ALT in
this study. We thought these might be due to small number
of cases studied, and this issue will be addressed in the
future study.
The CD4 cell count was higher in the anti-HDV seropos-
itive group, the percentage of CD4 cell count < 500 cells/mL
was higher in the anti-HDV seronegative group, and HIV RNA
viral load was higher among those in the anti-HDV sero-
negative group. Besides, no significant difference betweenCD4 cell count, HIV RNA viral load, and anti-HDV was noted
in this study. We think that HIV RNA viral load and CD4 cell
count are not related to anti-HDV infection in HBsAg sero-
positive IDUs, and it is also possible that anti-HDV has an
influence on HIV infection among IDUs.
The limitation of this study is that the IDUs in this study
were prisoners, so visiting and following them up was very
difficult, and thus data collected, such as serial changes in
the disease course and therapy given, could not be assessed
completely. In addition, the number of cases studied is
small, and therefore some analysis did not show significant
difference, although we think that the difference is
reasonable.Conclusion
The prevalence of anti-HDV seropositivity among HBsAg
seropositive IDUs was 68.9%, and this rate was higher among
IDUs with HIV infection than among those without HIV
infection; additionally, anti-HIV seropositivity was related
to anti-HDV seropositivity. Abnormal ratios of AST/ALT and
CD4 cell count were not related to anti-HDV among HBsAg
seropositive IDUs. In Taiwan, because HDV infection among
IDUs is becoming severe gradually, we suggest that for IDUs,
HBsAg, and anti-HDV should be closely monitored. We also
recommend that abstinence from drug abuse is a very
important method that can prevent HBV and HDV infection
in these individuals.Acknowledgments
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